Ascendis Pharma Files 6-K for S-8 Registration
Ticker: ASND · Form: 6-K · Filed: Jun 2, 2025 · CIK: 1612042
Sentiment: neutral
Topics: sec-filing, 6-K, registration
TL;DR
Ascendis Pharma filed a 6-K, mostly procedural stuff for stock plans. No major news.
AI Summary
Ascendis Pharma A/S filed a Form 6-K on June 2, 2025, to incorporate by reference into its existing S-8 registration statements. These statements relate to the company's equity compensation plans.
Why It Matters
This filing is procedural and relates to the company's ongoing equity compensation plans, indicating continued employee incentive programs.
Risk Assessment
Risk Level: low — The filing is a routine administrative submission and does not contain new financial or operational information that would typically impact risk.
Key Players & Entities
- Ascendis Pharma A/S (company) — Registrant
- 001-36815 (company) — Commission File Number
- 333-203040 (company) — Form S-8 Registration Number
- 333-210810 (company) — Form S-8 Registration Number
- 333-211512 (company) — Form S-8 Registration Number
- 333-213412 (company) — Form S-8 Registration Number
- 333-214843 (company) — Form S-8 Registration Number
- 333-216883 (company) — Form S-8 Registration Number
- 333-228576 (company) — Form S-8 Registration Number
FAQ
What is the purpose of this Form 6-K filing by Ascendis Pharma A/S?
The Form 6-K is being filed to incorporate by reference into the registrant's registration statements on Form S-8.
What are the Form S-8 registration numbers mentioned in the filing?
The filing lists several Form S-8 registration numbers: 333-203040, 333-210810, 333-211512, 333-213412, 333-214843, 333-216883, and 333-228576.
When was this Form 6-K filed?
This Form 6-K was filed on June 2, 2025.
What is the principal executive office address of Ascendis Pharma A/S?
The principal executive offices are located at Tuborg Boulevard 12, DK-2900 Hellerup, Denmark.
Does Ascendis Pharma A/S file annual reports under Form 20-F or 40-F?
Ascendis Pharma A/S indicates that it files annual reports under Form 20-F.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on June 2, 2025 regarding Ascendis Pharma A/S (ASND).